Investor Relations News QIV 2016

End-of-the-year Review by Dr. Wolfgang Brysch, CEO of MetrioPharm

Dear shareholders,

Once more we have had the most successful year in our company's history. This statement has been frequently used in my year-end messages and its repetition should not be seen as lack of imagination. It rather reflects the constant and encouraging progress that we are making, especially with our lead product MP1032. The successful completion of patient recruitment for our phase IIa study in psoriasis, which started in May, marks an important milestone that we had set for 2016. On December 29, the last patient is expected to complete his last control visit and all patient data can be entered into the database. In the beginning of next year, the data are checked and statistically evaluated until the (anticipated) unblinding, i.e. the disclosure of the placebo and drug patients, and the announcement of the data in March 2017. Thus, the beginning of the new year remains exciting.

In 2016, we were also able to make substantial progress in our management and financing structure. The two most important milestones were the appointment of Dr. Sylvie Grégoire as new Executive Board President and the completion of our CII financing round with a total volume of CHF 9.4 million. With Dr. Sylvie Grégoire, we were able to attract a very experienced and internationally highly regarded pharma executive to our management team. During her career, Sylvie has been involved in the successful development and market registration of 15 new drugs. She held top positions in several biotech and pharma companies, which enjoyed outstanding business success during her tenure.

Together with the entire scientific, administrative, and management team of MetrioPharm, I wish all of you an enjoyable holiday season. I look forward to continue our journey with your ongoing support and shared success.

Yours sincerely,

Dr. Wolfgang Brysch
Chief Executive Officer

Wolfgang Brysch, Chief Executive Officer MetrioPharm AG


Feedback on the Perception Study

Dear shareholders,

In our last IR newsletter we asked you to participate in our online perception study. The restructuring of the Investor Relations department as well as the relaunch of our website and the annual report according to our new Corporate Design and Communication Guidelines were the main triggers for this study. More than 100 shareholders have given us their opinion in the four areas of information, company valuation, stock trading, and communication instruments. We would like to take this opportunity to thank you very much for participating!

We are pleased that you are generally satisfied with the quality of our work and have received the following suggestions for our future work:

  •     We are working on providing you with more information regarding the performance and purchase and sale opportunities of our shares in the future.
  •     Beginning with our next newsletter, there will be a column with brief general information on the biotech and pharma sector.
  •     We will continue to work on improving the presence and image of MetrioPharm in the media.

We thank you for your feedback and will implement the above mentioned recommendations during the next year.

Yours sincerely,
Eva Brysch
Manager Investor Relations & Corporate Communications

Eva Brysch, MetrioPharm, Manager Investor Relations & Corporate Communications


MetrioPharm AG was present at German Equity Forum 2016

MetrioPharm AG was represented at this year's German Equity Forum by Dr. Wolfgang Brysch, Chief Executive Officer, and Eva Brysch, Investor Relations Manager. In addition to new valuable contacts with interested investors, analysts, and brokers, MetrioPharm AG was able to introduce itself to an interested audience on November 23 during the Venture Day.

Dr. Wolfgang Brysch presented the company successfully in front of venture capital and private equity investors.

MetrioPharm AG at German Equity Forum 2016


Financial Calendar of MetrioPharm AG in QI 20177

09-11 January 2017: Biotech Showcase 2017, San Francisco, USA

MetrioPharm AG will be represented at Biotech Showcase in San Francisco, USA, from January 9th to 11th by Dr. Sylvie Grégoire, Executive President of the Board of Directors, and Dr. Wolfgang Brysch, Chief Executive Officer. Within the framework of Biotech Showcase and the parallel running J.P. Morgan Healthcare Conference, Dr. Grégoire and Dr. Brysch will meet with various healthcare investors and potential pharmaceutical partners.

In addition, MetrioPharm AG will present itself to a broad US audience on January 11. The presentation will be given by Dr. Sylvie Grégoire.

MetrioPharm AG Newsletter Download PDF